AI-CVD vs PMcardio

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI-CVD

by HeartLung Corporation

PMcardio

by Powerful Medical

AI Verdict

Both AI-powered tools focus on cardiology, but they utilize different diagnostic modalities. AI-CVD leverages existing CT scans for opportunistic screening of cardiovascular and multisystem diseases, while PMcardio interprets ECGs to assess a wide range of cardiac conditions. Therefore, the choice between them depends on whether the user prioritizes CT-based screening or ECG interpretation at the point of care.

Choose AI-CVD if…

Choose AI-CVD if your primary goal is opportunistic screening for a broad range of cardiovascular and multisystem diseases using existing CT scans. This tool excels at identifying hidden health risks by performing automated measurements like coronary artery calcium (CAC) scoring, aortic valve calcification, and epicardial fat volumetry, without requiring additional imaging or disrupting workflow. It's ideal for comprehensive risk stratification and early detection of conditions that might otherwise go unnoticed.

View AI-CVD →

Choose PMcardio if…

Choose PMcardio if your focus is on rapid and accurate interpretation of ECGs for the assessment of over 50 cardiac conditions, particularly in acute care settings or where immediate expert-level analysis is crucial. This tool is highly effective for detecting time-critical events like STEMI/OMI, reduced LVEF, and various arrhythmias, empowering clinicians at the point of care, including paramedics and emergency physicians. It can also digitize and improve the quality of old or distorted ECGs.

View PMcardio →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AI-CVD	PMcardio
Pricing	Contact for pricing	Freemium
Deployment	Cloud	Mobile app (iOS and Android), Web platform, Enterprise integrations with EHR/CVIS and EMS systems
FDA Status	1 AI-estimated	Pending AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

PMcardio

PMcardio offers deployment as a mobile app and web platform, allowing clinicians to start using it immediately without IT integration. It also supports various ECG formats and provides a user-friendly interface with features like AI explainability. AI-CVD, while cloud-deployed, does not provide details on its user interface or ease of immediate use.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AI-CVD	PMcardio
Name	AI-CVD	PMcardio
Company	HeartLung Corporation	Powerful Medical
Description	FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.	CE-certified AI platform that interprets ECGs to assess over 50 cardiac conditions rapidly and accurately.
Regulatory Clearance	FDA-cleared	CE-certified
Key Features (Examples)	Automated CT-derived anatomical and density-based measurements, Opportunistic screening from existing chest and abdominal CT scans, Coronary Artery Calcium (CAC) scoring	Instant AI-powered ECG interpretations, Detection of 50+ ECG findings (including STEMI/OMI, rhythms, reduced LVEF, conduction disorders), Visual AI Explainability with heatmaps

Videos

Demos, reviews, and walkthroughs featuring AI-CVD and PMcardio.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows for different specialties?

AI-CVD is designed for opportunistic screening using existing CT scans, fitting into radiology and cardiology workflows without requiring additional imaging or workflow disruption. PMcardio, on the other hand, integrates with EHR/CVIS and EMS systems, and is available as a mobile and web platform, making it suitable for point-of-care ECG interpretation in cardiology, emergency medicine, and internal medicine.

What is the depth of EHR integration for each tool, and how does it impact data flow and physician interaction?

AI-CVD's integration focuses on leveraging existing CT scan data, implying a data flow from imaging systems to the platform for analysis. PMcardio offers enterprise integrations with EHR/CVIS and EMS systems, suggesting a more direct and potentially bidirectional data exchange for ECG interpretations and clinical decision support at the point of care.

What specific clinical conditions can each tool accurately detect, and what is their reported sensitivity for these conditions?

AI-CVD performs opportunistic screening for cardiovascular and multisystem diseases, including coronary artery calcium scoring, aortic and mitral valve calcium analysis, cardiac chamber volumetry, and epicardial fat volumetry. PMcardio detects over 50 cardiac conditions from ECGs, including STEMI/OMI, reduced LVEF, rhythms, and conduction disorders, with features like 'Queen of Hearts' for STEMI/OMI detection and 'LVsense' for reduced LVEF detection.

What is the expected learning curve for physicians and their teams to effectively utilize each tool?

AI-CVD, by leveraging existing CT scans and providing automated measurements, may have a relatively low learning curve for interpreting its output within existing radiology and cardiology contexts. PMcardio, with its instant AI-powered ECG interpretations and visual AI explainability ('ECGxplain'), aims to provide rapid, expert-level interpretations, suggesting a focus on ease of use for various healthcare professionals at the point of care.

Beyond HIPAA, what security measures are in place to protect patient data when using these tools?

While both tools are likely HIPAA compliant, AI-CVD's cloud deployment for CT scan analysis would necessitate robust data encryption and access controls. PMcardio's mobile and web platform, along with enterprise integrations, would require secure data transmission protocols, authentication mechanisms, and potentially device-level security for its mobile application to protect patient ECG data.

Are there audit-trail features available in either tool to track how AI interpretations are used and modified by clinicians?

PMcardio's 'Pro Plan' offers extended report history, which could imply some level of audit trail for ECG analyses. For AI-CVD, given its focus on quantitative imaging, audit trails would likely involve tracking access to results and any subsequent clinician modifications or annotations of the AI-generated measurements.

How do these tools support multi-site rollouts, and what considerations should be made for consistent implementation across different clinical settings?

AI-CVD's cloud-based deployment could facilitate multi-site rollouts by providing centralized access to the platform for CT scan analysis across different locations. PMcardio's web platform and enterprise integrations, alongside its mobile app, offer flexibility for deployment across various clinical settings, from individual clinicians to large healthcare systems, requiring consistent integration strategies and user training.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring AI-CVD or PMcardio

Backers

Who funded each tool's parent company.

PMcardio

LifeX Ventures